Literature DB >> 9840926

A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells.

R Pochampally1, B Fodera, L Chen, W Shao, E A Levine, J Chen.   

Abstract

The MDM2 oncogene product is a regulator of the p53 tumor suppressor. MDM2 is cleaved by Caspase 3 (CPP32) during apoptosis after aspartic acid-361, generating a 60 kd fragment. Here we report that human tumor cell lines often express high levels of a 60 kd MDM2 isoform (p60) in the absence of apoptosis. We demonstrate that p60 is a product of caspase cleavage of full length MDM2 after residue 361. The protease that cleaves MDM2 in non-apoptotic cells appears to be distinct from the apoptosis-specific Caspase 3, since Caspase 3 substrate poly(ADP-ribose) polymerase (PARP) is not cleaved in cells producing p60. The p60 form of MDM2 is a significant fraction of the p53-bound MDM2 protein in certain tumor cells, suggesting that it functions in the regulation of p53. p60 is also detected in breast tumors overexpressing MDM2. These observations suggest that MDM2 is regulated by caspase processing in non-apoptotic cells, and may account for the MDM2 proteins of similar mobility seen in tumors and other cell lines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840926     DOI: 10.1038/sj.onc.1202206

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  Cotranscriptional exon skipping in the genotoxic stress response.

Authors:  Martin Dutertre; Gabriel Sanchez; Marie-Cécile De Cian; Jérôme Barbier; Etienne Dardenne; Lise Gratadou; Gwendal Dujardin; Catherine Le Jossic-Corcos; Laurent Corcos; Didier Auboeuf
Journal:  Nat Struct Mol Biol       Date:  2010-10-24       Impact factor: 15.369

3.  Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops.

Authors:  Tzu-Hao Cheng; Stanley N Cohen
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

4.  Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.

Authors:  Li-Ju Chang; Alan Eastman
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

5.  Caspase-mediated cleavage of eukaryotic translation initiation factor subunit 2alpha.

Authors:  S Satoh; M Hijikata; H Handa; K Shimotohno
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

6.  Zinc deficiency causes neural tube defects through attenuation of p53 ubiquitylation.

Authors:  Huili Li; Jing Zhang; Lee Niswander
Journal:  Development       Date:  2018-12-13       Impact factor: 6.868

7.  A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene.

Authors:  S Bartl; J Ban; H Weninger; G Jug; H Kovar
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

8.  Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels.

Authors:  Moussa Alkhalaf; Abdalla M El-Mowafy; Laila A Abou-Zeid
Journal:  J Mol Genet Med       Date:  2005-08-19

9.  Curcumin homing to the nucleolus: mechanism for initiation of an apoptotic program.

Authors:  Mistuni Ghosh; Robert O Ryan
Journal:  J Nutr Biochem       Date:  2014-08-01       Impact factor: 6.048

10.  MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.

Authors:  Li-Yan Khor; Kyounghwa Bae; Rebecca Paulus; Tahseen Al-Saleem; M Elizabeth Hammond; David J Grignon; Mingxin Che; Varagur Venkatesan; Roger W Byhardt; Marvin Rotman; Gerald E Hanks; Howard M Sandler; Alan Pollack
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.